SNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Sanofi's research and development for the three months ended in Dec. 2013 was $1,698 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $6,370 Mil.
This is the expense the company spent on research and development.
Sanofi Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 1505.86701434 (Mar. 2013 ) + 1552.35602094 (Jun. 2013 ) + 1613.9154161 (Sep. 2013 ) + 1697.54768392 (Dec. 2013 ) = $6,370 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Sanofi Annual Data
|Research & Development||3,133||4,904||5,754||6,682||6,060||6,538||6,079||6,178||6,523||6,499|
Sanofi Quarterly Data
|Research & Development||1,677||1,639||1,542||1,517||1,484||1,801||1,506||1,552||1,614||1,698|